Synaptogenix Inc (SNPX)

[Cyosol]

Any improvement over placebo with a two-sided p-value below 0.05.

First trial had a 2.6 point improvement over placebo but it got slammed for having a one-sided p-value of 0.07.

Second trial went so bad they didn't even need p-values.

Most of the optimism comes from analyzing subgroups post-hoc, but that's not going to impress markets.

For those that weren't there, here's what they wrote about the first trial:

https://www.science.org/content/blog-post/neurotrope-shameful-pr-stunt

https://www.thestreet.com/investing/stocks/a-neurotrope-stock-promotion-scheme-is-underway-but-who-s-paying-for-it-14117285

Note that there's no such articles about the second trial.